noom glp 1 microdose introduces longevity-focused GLP-1 microdosing with at-home biomarker tracking Noom Med - GLP-1 Medications
Description
$LLY -0.60% today as Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes More Info:
Product Benefits
95% CI: 0.8, 0.9
GLP-1 agonists are powerful weight loss tools, but certain medications can reduce their effectiveness or cause harmful interactions
Berberine has been studied
March 31, 2025
